Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

SPRY

ARS Pharmaceuticals (SPRY)

ARS Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SPRY
DateTimeSourceHeadlineSymbolCompany
30/04/202423:01GlobeNewswire Inc.ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New ZealandNASDAQ:SPRYARS Pharmaceuticals Inc
04/04/202400:01GlobeNewswire Inc.ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)NASDAQ:SPRYARS Pharmaceuticals Inc
22/03/202407:05GlobeNewswire Inc.ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:SPRYARS Pharmaceuticals Inc
08/03/202408:05GlobeNewswire Inc.ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor DayNASDAQ:SPRYARS Pharmaceuticals Inc
08/03/202404:56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPRYARS Pharmaceuticals Inc
07/03/202401:01GlobeNewswire Inc.ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024NASDAQ:SPRYARS Pharmaceuticals Inc
02/03/202412:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
29/02/202413:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
27/02/202404:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
27/02/202401:01GlobeNewswire Inc.ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical studyNASDAQ:SPRYARS Pharmaceuticals Inc
23/02/202401:01GlobeNewswire Inc.ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024NASDAQ:SPRYARS Pharmaceuticals Inc
21/02/202401:01GlobeNewswire Inc.ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response LetterNASDAQ:SPRYARS Pharmaceuticals Inc
06/02/202401:01GlobeNewswire Inc.ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual MeetingNASDAQ:SPRYARS Pharmaceuticals Inc
05/01/202408:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
05/01/202408:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
05/01/202408:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
05/01/202408:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRYARS Pharmaceuticals Inc
10/11/202308:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPRYARS Pharmaceuticals Inc
10/11/202308:00GlobeNewswire Inc.ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:SPRYARS Pharmaceuticals Inc
10/11/202303:02GlobeNewswire Inc.ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisNASDAQ:SPRYARS Pharmaceuticals Inc
07/10/202300:57Dow Jones NewsARS Pharmaceuticals to Meet With FDA on Neffy RejectionNASDAQ:SPRYARS Pharmaceuticals Inc
07/10/202300:03GlobeNewswire Inc.ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)NASDAQ:SPRYARS Pharmaceuticals Inc
04/10/202300:03GlobeNewswire Inc.Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical ImmunologyNASDAQ:SPRYARS Pharmaceuticals Inc
26/09/202306:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPRYARS Pharmaceuticals Inc
21/09/202300:20Dow Jones NewsARS Pharmaceuticals Shares Sink to New Lows on FDA Neffy SetbackNASDAQ:SPRYARS Pharmaceuticals Inc
20/09/202320:30Dow Jones NewsARS Pharmaceuticals Shares Sink Premarket as FDA Rejects Neffy SprayNASDAQ:SPRYARS Pharmaceuticals Inc
20/09/202320:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPRYARS Pharmaceuticals Inc
20/09/202312:49GlobeNewswire Inc.FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional StudyNASDAQ:SPRYARS Pharmaceuticals Inc
02/09/202306:15Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SPRYARS Pharmaceuticals Inc
11/08/202306:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SPRYARS Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SPRY